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Malaria aminopeptidases are important in the generation and
regulation of free amino acids that are used in protein anabolism
and for maintaining osmotic stability within the infected erythro-
cyte. The intraerythrocytic development of malaria parasites is
blocked when the activity of aminopeptidases is specifically inhib-
ited by reagents such as bestatin. One of themajor aminopeptidases
of malaria parasites is a leucyl aminopeptidase of the M17 family.
We reasoned that, when this enzymewas the target of bestatin inhi-
bition, its overexpression in malaria cells would lead to a reduced
sensitivity to the inhibitor. To address this supposition, transgenic
Plasmodium falciparum parasites overexpressing the leucyl amin-
opeptidase were generated by transfection with a plasmid that
housed the full-length gene. Transgenic parasites expressed a
65-kDa protein close to the predicted molecule size of 67.831 kDa
for the introduced leucyl aminopeptidase, and immunofluores-
cence studies localized the protein to the cytosol, the location of the
native enzyme. The product of the transgene was shown to be func-
tionally active with cytosolic extracts of transgenic parasites exhib-
iting twice the leucyl aminopeptidase activity compared with wild-
type parasites. In vitro inhibitor sensitivity assays demonstrated that
the transgenic parasites were more resistant to bestatin (EC50 64 M)
compared with the parent parasites (EC50 25 M). Overexpression of
genes inmalaria parasites would have general application in the iden-
tification and validation of targets for antimalarial drugs.
During the development and asexual reproduction of malaria para-
sites within erythrocytes, as much as 65–75% of erythrocyte hemoglo-
bin is internalized and digested (1, 2). There is still some conjecture as to
the reason why the parasite needs to degrade such a large proportion of
the erythrocyte hemoglobin, but several theories have been proposed (3,
4). It has been known for some time thatmalaria parasites require amino
acids derived from host hemoglobin for protein synthesis and develop-
ment (4), although recent studies suggest that the fraction of digested
hemoglobin used for this purpose is surprisingly small (in the region of
16%) (5). Malaria parasites acquire additional amino acids from the
extracellular medium and incorporate these into their proteins (5–7)
and at the same time extrude unneeded amino acids through new per-
meability pathways that appear in the infectedhost cellmembranes (8). It is
now believed that the excess hemoglobin digestion is necessary to reduce
the colloid-osmotic pressure within the infected erythrocyte and thus pre-
vent premature cell lysis (9). Apart from contributing to the regulation of
the internal osmotic pressure, the constant influx and efflux of amino acids
may also ensure that there is a sufficient supply of each amino acid, espe-
cially those that are rare in hemoglobin (isoleucine, cysteine, glutamine,
methionine, and glutamate), for protein synthesis (3, 7).
Hemoglobin is endocytosed into double membrane vesicles that bud
off from the cytosome of the parasite and are transported to the acidic
digestive vacuole (DV)5 (10, 11). Within this specialized organelle,
hemoglobin is digested by endopeptidases at a pH of5.5 in a semior-
dered fashion, initially at the hinge region by the aspartic peptidases
plasmepsins I and II and then further by the aspartyl peptidases I, II, and
IV, and the histoaspartic peptidase and three cysteine peptidases, falci-
pain-2, -2, and -3 (1, 3, 10, 11). Peptides generated from this digestion
are processed by ametalloprotease, falcilysin, into short oligopeptides of
5–10 amino acids and then by a dipeptidyl aminopeptidase I, which
reduces these to dipeptides (12). However, free amino acids are not
generated within the DV, as no exoaminopeptidase activity has been
detected in isolated DV (13) and in vitro digestion of hemoglobin by
extracts of DVs does not generate free amino acids (13, 14). Accord-
ingly, we and others have suggested that peptides/dipeptides produced
within the digestive vacuole are transported outside for conversion into
individual amino acids (13–16).
Leucyl aminopeptidase-like activity has been detected in the soluble
extracts of various Plasmodium species and functions in the release of
hemoglobin-derived amino acids (13–21). The activity separates into
the cytosolic fraction of the parasite, exhibits a pHoptimumvalue of 7.2,
and is inactive below pH 6.0, which is consistent with a function outside
theDVs (13).Plasmodium falciparum aminopeptidase activity, partially
purified by affinity chromatography employing the inhibitor bestatin as
a ligand, cleaved synthetic peptides representative of the products of
endopeptidase-degraded hemoglobin (13, 15) and exhibited a general
preference for substrates containing leucine and alanine at the N termi-
nus (amino acids that constitute 25% of the amino acid residues in
human hemoglobin) (15). Aminopeptidase activity predominates in
trophozoites, and the greatest in vitro growth inhibition by bestatin and
nitrobestatin occurs when parasites are at the late ring and early tropho-
zoite stage (13). This coincides with the period of increased metabolic
activity within the infected erythrocyte, increased hemoglobin diges-
tion, the induction of new permeability pathways, and rapid growth of
the parasite (4, 8, 9).
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The leucyl aminopeptidase-like activity detected in soluble extracts of
malaria parasites could be derived from two distinct aminopeptidases
that display overlapping substrate specificities. The first is represented
by a previously characterized 122-kDa zinc aminopeptidase of the M1
family, which may be membrane-bound but processed to two soluble
forms of 96 and 68 kDa (21, 22). The second is the product of a gene
described in the present study that encodes a 67.831-kDa leucyl amin-
opeptidase of the M17 family (13–15). We have overexpressed the M17
leucyl aminopeptidase gene inmalaria parasites and shown that functional
enzyme is expressed in the cytosol of transgenic parasites, the same com-
partment as the native enzyme (13, 15). More importantly, we have dem-
onstrated thatmalariaparasitesoverexpressingM17 leucyl aminopeptidase
are more resistant to killing by bestatin, an aminopeptidase inhibitor with
antimalarial activity compared with wild-type parasites.
EXPERIMENTAL PROCEDURES
Parasites—P. falciparum clone D10 derived from P. falciparum iso-
late FC27 was obtained from The Walter and Eliza Hall Institute, Mel-
bourne, Australia. Parasites were cultured as described previously (23).
Construction of the Transgenic Expression Plasmids and Transfection
ofMalaria Parasites—Pf14_0439, as annotated by PlasmoDB (plasmod-
b.org), is a gene located on chromosome 14 of P. falciparum. It consists
of a single exon of 1818 bp that encodes a 605-amino-acid protein of the
M17 leucyl aminopeptidase family. A PCR fragment corresponding to
the predicted mRNA/RNA sequence was amplified from DNA isolated
from P. falciparum clone D10. The forward primer for Pf14_0439 was
AP14F (AGATCTATGTATTTTTCTTCCTTATGT) and contained a
BglII restriction site (in bold). The reverse primer was AP14R (CTG-
CAGTAGAGCGTCATTGAGTACAAA) and contained a PstI site (in
bold) but not the putative stop codon of the gene. The PCR products
were cloned into pGEM using a TA cloning system (Promega) and
sequenced to confirm that no Taq-associated errors have been intro-
duced into the DNA. The full-length fragment was digested out of the
pGEMvector using the appropriate restriction enzymes and ligated into
the GatewayTM-compatible entry vector pHcmycB (Gateway, Invitro-
gen) that had previously been digested using BglII and PstI. A c-Myc tag
was ligated in-frame at the 3 end of the introduced gene sequence. This
vector is a variant of the pHGB vector described by Tonkin et al. (24), in
which the c-Myc 10-amino-acid epitope tag flanked by a 5 PstI site and
a 3 NsiI site has been cloned into the original PstI site of pHGB. The
entry vector containing the Pf14_0439 transgene was designated
pHAP14cmycB. A clonase reactionwas then performed using this entry
vector and a GatewayTM-compatible destination vector. The destina-
tion vector contained not only a GatewayTM destination cassette but
also a second cassette comprising the human dihydofolate reductase
synthetase gene under the control of the P. falciparum calmodulin pro-
moter. This second cassette acts as a selectable marker in P. falciparum.
This final plasmid was designated pHH1-HAP14cmycB.
Ring-stage parasites were subjected to electroporation in the pres-
ence of 150 g of plasmid as described previously (25). Parasites resist-
ant to WR99210 were obtained 15–22 days later.
Northern Blotting—Northern blotting was carried out essentially as
described previously using total RNA extracts from trophozoite stage par-
asites (26).Todistinguishbetween transgene andendogenous gene expres-
sion, the blot was probed with a DNA fragment containing the c-Myc
epitope tag and the 3 untranslated region (UTR) of the transgene labeled
with [-32P]dATP by random priming (DECAprime II, Ambion).
Immunoblotting—Proteins of saponin-lysed parasite extracts were
resolved by reducing 10% SDS-polyacrylamide gels and transferred to
nitrocellulose membrane using a semidry electroblotter (Trans-Blot,
Bio-Rad) (26). The membranes were probed with a mouse monoclonal
antibody to c-Myc (1:2500 dilution; Sigma) followed by a horseradish
peroxidase-labeled anti-mouse IgG antibody (1:5000 dilution, Chemi-
con International Inc.). Themembrane was stripped and reprobed with
an anti-glyceraldehyde-3-phosphate dehydrogenase mouse mono-
clonal antibody (1:2000 dilution) to demonstrate equal loading and
transfer of malaria proteins (26).
Immunofluorescence Analysis of Parasites—Acetone-fixed thin blood
smears of the transgenic parasite and wild-type D10 were probed with a
mouse monoclonal antibody to c-Myc (1:2000) and bound antibody
visualized with goat anti-mouse IgG-Cy2 (10 g/ml) (26). The parasite
nuclei were visualized with Hoechst dye (0.5 g/ml). The slides were
viewed with a fluorescence microscope (1000 magnification).
Assays for Leucine Aminopeptidase Activity—Aminopeptidase activ-
ity was measured by monitoring the release of the leaving group 7-ami-
no-4-methyl-coumarin (NHMec) from the fluorogenic peptide sub-
strates H-leucine-NHMec and H-alanine-NHMec (13, 15). Samples of
soluble parasite extracts were added to the substrate (10 M) in phos-
phate-buffered saline in a final volume of 200l in wells of a 96-microti-
tre plate. The reaction wasmonitored at 37 °C over a 30-min period in a
spectrofluorimeter with excitation at 370 nm and emission at 440 nm.
Protein assays were performed using the BCA protein acid kit employ-
ing bovine serum albumin as a standard.
Parasite Growth and Sensitivity to Inhibitors—The in vitro sensitivi-
ties of the wild-type and transfected parasite populations to the amin-
opeptidase inhibitor bestatin {(-)-N-[(2S,3R)-3-amino-2-hydroxy-4-
phenyl-butyryl]-L-leucine} (Sigma) were determined using the
[3H]hypoxanthine incorporation assay (27). Serial dilutions of inhibitor
were prepared in culturemedium (0.05–50M) and addedwith [3H]hy-
poxanthine (0.5Ci/well) to asynchronous cultures at a 0.5% parasitae-
mia and 2% hematocrit. After a 48-h incubation, the amount of [3H]hy-
poxanthine incorporated into the parasites was measured, and the
concentrations of inhibitor required to prevent incorporation by 50%
(EC50) were determined by linear interpolation of inhibition curves (28).
Each assay was performed in triplicate on three separate occasions, and
data were pooled and are presented as mean S.E.
RESULTS
Transfection of Plasmid pHH1-HAP14cmycB Generates an Amin-
opeptidase Transgenic Parasite—P. falciparum clone D10 ring-stage
parasiteswere transfectedwith the Pf14_0439 transgene and selected on
WR99210. Parasites resistant to WR99210 were observed 15–22 days
later. DNA was extracted when transgenic cultures reached 1% parasi-
taemia and the presence of the plasmid determined by PCR amplifica-
tion using vector-specific primers located in the heat shock protein 86 5
UTR and the Plasmodium berghei dihydrofolate reductase 3 UTR (i.e.
flanking the inserted aminopeptidase gene) (24). Gel analysis of the
PCR-generated DNA revealed a band of 2 kb for pHH1-HAP14cmycB
(Fig. 1A), the expected size for theM17 aminopeptidase gene plus addi-
tional vector sequence. The transgenic parasite cultures were main-
tained on WR99210 selection thereafter to sustain the episomally car-
ried plasmids. The growth rate and intraerythrocytic development of
the transgenic parasites were not distinguishable from wild-type para-
sites (data not shown).
TheAminopeptidase Transgene Is Transcribed andTranslated—North-
ernblot analysis showed that thepHH1-HAP14cmycB-transfectedmalaria
parasite cultures transcribed a single species of mRNA with an apparent
size of 2.3 kb (Fig. 1B)whenhybridizedusing aDNA fragment correspond-
ing to the c-Myc tag and the 3UTRof the transgene.When saponin-lysed
parasite-infected erythrocytes of the same cultures were probed by immu-
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noblotting with anti-c-Myc tagmonoclonal antibody, a single protein with
an apparentmolecularmass of 65 kDa (slightly smaller than the theoretical
molecular mass of 67.831 kDa) was detected (Fig. 1C).
Immunolocalization of Transgene Products—To determine the cellu-
lar location of the protein product of the leucyl aminopeptidase trans-
gene, an immunofluorescence assay was performed using anti-c-Myc
monoclonal antibody (Fig. 2). A diffuse staining characteristic of local-
ization to the parasite cytoplasm was observed. Staining with the anti-
serum was observed only in parasitized red blood cells as confirmed by
nuclear staining withHoechst dye (Fig. 2), and no staining was observed
in the wild-type D10 parasites (Fig. 2).
The Pf14_0439 Transgene Expresses a Functional Protein—Soluble
extracts of malaria parasites were prepared and assayed for leucyl amin-
opeptidase activity using the fluorogenic substrates H-leucine-NHMec
and H-alanine-NHMec. The activity of these extracts against
H-leucine-NHMec was higher than against H-alanine-NHMec, which
would be expected of a M17 cytosolic leucyl aminopeptidase (29).
Malaria parasites transfected with the Pf14_0439 transgene exhibited
approximately twice the specific aminopeptidase activity (relative fluo-
rescence units/106 infected cells) against both substrates comparedwith
wild-type parasites (Fig. 3). Activity in all extracts was completely inhib-
ited by 10 M bestatin (data not shown).
The Transgenic P. falciparum Clone Has Altered Sensitivity to Amin-
opeptidase Inhibitors—Parasites transfected with pHH1-HAP14cmycB
and maintained on 50 nM WR99210 were more resistant to bestatin
than either D10 parent parasites or parasites transfected with the pHH1
vector without the AP14cmyc cassette and maintained under a similar
selection regime; the combined data of three separate tests showed that
the parasites exhibited an EC50 of 64, 25, and 20M, respectively (Fig. 4).
DISCUSSION
Aminopeptidases are exopeptidases that catalyze the sequential
removal of amino acids from the N termini of peptides and play a major
role in regulating the balance between catabolism and anabolism in all
living cells. Inmalaria parasites, leucyl aminopeptidase-like enzymes are
believed to function in the terminal stages of hemoglobin digestion to
generate free amino acids that are then used for parasite protein synthe-
sis (13–15). Because malaria parasites also use amino acids taken from
their external environment for protein synthesis, it appears that the
aminopeptidases may also be important in regulating the internal free
amino acid pool for additional purposes, including maintenance of the
osmotic stability of the cell (9).
Two leucyl aminopeptidase-like enzymes are expressed by malaria
parasites, a 122-kDamembrane alanine aminopeptidase of theM1 fam-
ily and a 67.8-kDa leucyl aminopeptidase of the M17 family (21, 22).
Aminopeptidases of theM1 family are generally considered to bemem-
brane-bound (30), but Florent and co-workers (22) have shown by sol-
uble extraction and immunofluorescence studies that 96- and 68-kDa
forms, presumably processed from the parentmolecule, are found in the
cytosol ofmalaria cells. TheM17 family of aminopeptidase, on the other
hand, are found in the cytosol of all cells and do not undergo processing
events (29). Both classes of enzyme exhibit optimal activity at neutral
pH and have similar preferences for amino acids, although as their
names imply, they show a preference for either alanine or leucine. These
overlapping biochemical features have led to confusion as to the true
nature of the leucine-aminopeptidase activitymeasured inmany studies
that used soluble extracts of malaria parasites as their enzyme source
(13–20) and to the identity of the target of aminopeptidase inhibitors
that have antimalarial activity. Recent studies (31, 32) usingmicroarrays
have provided expression profiles for the M1 and M17 aminopeptidase
throughout the intraerythrocytic stages of malaria parasites and dem-
onstrate that the both enzymes are most highly expressed in early tro-
phozoites, which is consistent with earlier biochemical studies (13, 15).
However, the expression level of theM17 leucyl aminopeptidase is18-
fold higher than theM1 aminopeptidase. The corollary of these findings
is that the M17 leucyl aminopeptidase is the predominant source of
leucyl aminopeptidase-like activity inmalaria parasites and thus is most
likely the subject of the previous biochemical and inhibitor studies.
In the present study, we have shown that the M17 leucyl aminopep-
tidase can be overexpressed in malaria cells by transfecting ring-stage
FIGURE 1. Transfection of P. falciparum parasites with gene encoding M17 leucyl
aminopeptidase. A, PCR amplification of DNA extracted from the transgenic parasite
Pf14_0439 clone (lanes 1–3) andwild-type parasite clone D10 (lanes 4–6). Lanes 1 and 4,
PCRs using primers humandihydrofolate reductase (hDHFR) forward and reverse, which
amplify the human dihydrofolate reductase gene from the vector pHH1-HAP14cmycB;
lanes 2 and 5, PCR with primers, which are vector-specific primers that flank the inserted
transgene; lanes 3 and 6, PCR using primers AP14F and AP14R, which amplify both the
endogenous and transgene copies of Pf14_0439. B, Northern blot using 20 g of RNA
fractionated on a 1% Tris acetate-EDTA gel and probedwith a DNA fragment containing
the c-Myc epitope tag and the 3 UTR of the transgene labeled with [-32P]dATP. AP14
refers to the transgenic parasite clone, whereas D10 is the wild-type parental clone. C,
Westernblot of saponin-lysedparasite extracts from the transgenic parasite clone (AP14)
and thewild-type parasite line D10 probed sequentially with antibodies to c-Myc (upper
panel) and glyceraldehyde-3-phosphatedehydrogenase (lower panel).
FIGURE 2. Immunofluorescence analysis of the transgenic parasites.Amousemono-
clonal antibody to c-Myc was used to probe Pf14_0439 transgenic (series i) and D10
wild-type parasites (series ii). A shows parasites under bright field illumination. B shows
specific green staining of the transgenic parasite (i), which is absent in the wild-type
parasite clone (ii). C, i and ii show parasite nuclei visualized with 4,6-diamidino-2-phe-
nylindole (Hoechst dye). D shows a merge of panels B and C.
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parasites with the transgene housed in the pHH1-HAP14cmycB vector
prepared in our laboratory. The transgene was transcribed and
expressed as a single 65-kDa protein. Immunofluorescence studies
showed that it was transported correctly to the cytosol, the site of the
native enzyme (13). Most importantly, enzymatic assays with specific
peptide substrates showed that the transfected malaria cells expressed
twice as much aminopeptidase activity as wild-type cells, which we can
presume is because of the proper folding and activation of the enzyme
synthesized from the transfected gene. The introduction of the trans-
gene did not alter the in vitro growth rate or viability of themalaria cells.
Accordingly, although we suggested that leucyl aminopepitdases are
important in the regulation of the free amino acid pool in malaria cells,
the increased enzyme activity within the cells did not upset this function
sufficiently to affect malaria growth. It is probable that cells that over-
expressed leucyl aminopeptidase to a lethal level were lost during the
selection of transgene-carrying parasites using WR99210.
Bestatin is a dipeptide originally isolated from filtrates of Streptomy-
ces olivoretticuli and has immunopotentiating and antitumor activity
(33, 34).We have reported that bestatin, which inhibits aminopeptidase
members of both theM1 andM17 families (27, 30), was a potent inhib-
itor of the in vitro growth of malaria parasites (13, 16). Exposure of
synchronized cultures ofP. falciparum cultures to bestatin and its deriv-
ative nitrobestatin indicated that late rings/trophozoites are the most
susceptible intraerythrocytic stage. This correlates with the time at
which hemoglobin is being degraded and used as a source of nutrient
FIGURE 3. Aminopeptidase activity in soluble
extracts of wild-type and transgenic P. falcipa-
rum (Pf). Enzyme activity in soluble extracts of
three separate preparations of wild-type (Pf_D10)
and transgenic (Pf14_0439) parasites was meas-
ured using the fluorogenic peptide substrates
H-Leu-NHMec (A) and H-Ala-NHMec (B) and
expressed as relative fluorescence units/106
malaria cells
FIGURE 4. Effect of bestatin on transgenic andwild-type P. falciparum. In vitro sensi-
tivity of Pf14_0439 transgenic parasites (—F—), D10 wild-type parasites (——), and
D10 parasites transfected with the pHH1 vector alone (—f—) to the aminopeptidase
inhibitor bestatin determined by [3H]hypoxanthine incorporation. Each assay was per-
formed in triplicate for each drug concentration and on three separate occasions; there-
fore, the data shown represents the mean S.E. of nine values.
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and also with the increased expression of both the M1 and M17 amin-
opeptidases (13, 21, 31, 32). Here we show that P. falciparum parasites
overexpressing the M17 leucyl aminopepidase are2-fold less suscep-
tible to killing by bestatin (EC50 64 M) compared with wild-type para-
sites (EC50 25 M). The natural interpretation of these results is that
higher amounts of bestatin, which binds aminopeptidases in an equimo-
lar ratio, are required to reduce the intracellular activity of leucyl amin-
opeptidase to lethal levels in malaria cells that express more of this
enzyme. By extension, our studies show that theM17 leucyl aminopep-
tidase is a target of bestatin in malaria cells.
During this study, malaria parasites were also transfected with the
gene encoding the M1 membrane alanyl aminopeptidase, but these
transgenic parasites did not exhibit an increase in aminopeptidase activ-
ity or a difference in susceptibility to bestatin compared wild-type
malaria cells (data not shown). Although immunoblotting demon-
strated that a protein of the expected molecular size (120 kDa) was
expressed by the transgenic parasites, this was not processed to the
soluble smallermolecular size forms of 96 and 68 kDa thatwere detected
in the native parasites by Florent and co-workers (22). The translated M1
aminopeptidase may not have been correctly folded and/or post-transla-
tionallymodified toproduce a functionally active enzyme, and thereforewe
cannotmake a conclusion on its potential as a target for bestatin-mediated
killing of malaria. In addition, we cannot exclude the possibility that over-
expression of the M17 leucyl aminopeptidase prevents killing of malaria
parasites by providing more enzyme to compete for bestatin binding and
preventing it from inhibiting theM1 aminopeptidase.
Cysteinyl (falcipain 1–3) and aspartyl (plasmepsins I–IV) endopepti-
dases are involved in the degradation of hemoglobinwithin the digestive
vacuole (1–4). Specific or broad range inhibitors of these endopepti-
dases block hemoglobin degradation and have potent effects onmalaria
growth, and therefore both enzyme classes are intensely studied as tar-
gets for new antimalarial drugs (3, 10, 35). Because cysteinyl and aspartyl
inhibitors exhibit synergistic activity when used together, combination
therapies are also possible (36). Gene disruption methods have been
used to explore the function of these enzymes and their role in hemo-
globin digestion. Disruption of the gene encoding falcipain 2 did not
result in complete ablation of cysteine endopeptidase activity but did
impair hemoglobin digestion and parasite growth (37), whereas disrup-
tion of falcipain 1 had no effect on either (38). Disruption of the genes
encoding falcipain 3 (37) and dipeptidyl aminopeptidase (12) is lethal to
malaria parasites, and hence these peptidases are considered critical to
survival within the erythrocyte.
As an alternative to employing gene disruption methods for studying
the importance of peptidases in malaria, we exploited the transfection
plasmids available in our laboratory to overexpress the M17 leucyl
aminopeptidase in malaria parasites. Tonkin et al. (24) described the
design of transfection vectors for producing proteins fused with the
reporter protein green fluorescent protein and exploited these to local-
ize malaria proteins to specific intracellular compartments, such as the
plastid andmitochondrion. In this study, these vectors were further modi-
fied by replacing the green fluorescent protein reporter with the signifi-
cantly smaller c-Myc epitope tag allowing production of functional mole-
cules that could be tracedwith anti-c-Myc antibodies.Using this approach,
we also identified the M17 aminopeptidase as a target for the antimalarial
activity of bestatin and therefore suggest that this could be a general
approach for the characterization and validation of malaria drug targets.
Cysteinyl or aspartyl inhibitors and bestatin show little synergy
against malaria parasites in vitro, most likely because the aminopepti-
dase functions in separate cell compartments from the endopeptidases
(39). However, a combination of drugs targeted at multiple exoamin-
opeptidases involved in amino acid regulation in the parasite cytosol
may offer a more reasonable proposition for combination therapies; the
targets would not only include the M17 leucyl aminopeptidase and M1
membrane alanine aminopeptidases but also two uncharacterized
enzymes expressed by the intraerythrocytic stages of malaria, namely
prolyl aminopeptidase and aspartyl aminopeptidases (plasmodb.org).
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